Of the millions of antibodies produced by the human immune system, Theraclone Sciences’ comprehensive screening technology rapidly identifies the rare few that have evolved to successfully cure infection and fight disease. For over a decade we perfected our platform technology to discover these human monoclonal antibodies for development as safe and effective therapeutic products.  We licensed our HIV broadly neutralizing fully-human antibodies to Gilead who are developing those as part of an HIV-cure regimen.  We also licensed our platform technology to OncoResponse for use in the field of oncology.  For more information visit

Theraclone Sciences

1124 Columbia Street, Suite 300

Seattle, WA 98104

P: 206.805.1600

F: 206.805.1699